Viking Therapeutics, Inc. (VKTX) belonging to the Healthcare sector has surged 8.59% and closed its last trading session at $10.62.
The company reported its EPS on 3/30/2018. Currently, the stock has a 1 Year Price Target of $14.25.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Viking Therapeutics, Inc. on 3/30/2018 reported its EPS as $-0.21 with the analysts projecting the EPS of the stock as $-0.2. The company beat the analyst EPS Estimate with the difference of $-0.01. This shows a surprise factor of -0.05%.
Many analysts have provided their estimated foresights on Viking Therapeutics, Inc. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.12.
Whereas they predicted High and Low Earnings Estimate as $-0.1 and $-0.14 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.21.
Viking Therapeutics, Inc. (VKTX) has the market capitalization of $502.22 Million. The company rocked its 52-Week High of $11.17 and touched its 52-Week Low of $0.88.
The stock has Return on Assets (ROA) of -59.4 percent. Return on Equity (ROE) stands at -79.7% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 161.58 Percent. The company has Beta Value of 0 and ATR value of 0.93. The Weekly and Monthly Volatility stands at 12.57% and 12.40%.